AWM
VERV

Avior Wealth Management’s Verve Therapeutics VERV Stock Holding History

Avior Wealth Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11
Closed -$146 – 3684
2024
Q1 		$146 Buy
+11
New +$146 ﹤0.01% 3016

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Avior Wealth Management's VERV Position: Q2 2024 in Review

Avior Wealth Management sold out of Verve Therapeutics (VERV) in Q2 2024, closing a stake of 11 shares — an estimated $146 sold.

Avior Wealth Management first reported a position in VERV in Q1 2024 and held it in 1 quarter. The position peaked at $146 in Q1 2024. 166 funds tracked by Wall St. Rank hold VERV as of Q2 2024.

  • Avior Wealth Management reported no remaining Verve Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 11 Verve Therapeutics shares in Q2 2024, an estimated $146.
  • Avior Wealth Management first reported a position in Verve Therapeutics in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Verve Therapeutics position peaked at $146 in Q1 2024.
  • 166 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.